Foghorn Therapeutics Inc. reports results for the quarter ended March 31 - Earnings Summary

• Foghorn Therapeutics Inc. FHTX.OQ reported a quarterly adjusted loss of 30 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -59 cents. The mean expectation of six analysts for the quarter was for a loss of 34 cents per share. Wall Street expected results to range from -55 cents to -24 cents per share.

• Revenue rose 17.9% to $5.95 million from a year ago; analysts expected $5.82 million.

• Foghorn Therapeutics Inc.'s reported EPS for the quarter was a loss of 30 cents​.

• The company reported a quarterly loss of $18.83 million.

• Foghorn Therapeutics Inc. shares had risen by 18.6% this quarter and lost 8.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 8.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Foghorn Therapeutics Inc. is $10.00

This summary was machine generated from LSEG data May 14 at 12:11 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)